GlassScriptPhysician profile
John Dowlen
NPI 1487253035
$6,656.95
in general payments reported to CMS, 2019-2025
24 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $1,563 · 2023: $1,735 · 2024: $1,744 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Education: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.00 |
| Education | $559.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $927.85 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $905.59 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $766.86 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $680.10 | 2022-2025 | |
| Lilly USA, LLC | $532.22 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $481.97 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $459.92 | 2021-2025 | Opzelura |
| Ucb, INC. | $449.40 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $382.71 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $236.53 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $163.11 | 2021-2025 | |
| Organogenesis INC. | $115.05 | 2024-2025 | Novachor |
| Mayne Pharma Commercial LLC | $104.80 | 2022-2024 | |
| Dermavant Sciences, INC. | $76.51 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $68.85 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $63.72 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Leo Pharma INC. | $54.59 | 2023-2025 | Anzupgo, Adbry |
| Mallinckrodt Hospital Products INC. | $40.09 | 2021-2024 | Acthar |
| Cipher Pharmaceuticals US LLC | $36.94 | 2025 | Spinosad, Natroba |
| Mylan Institutional INC. | $35.58 | 2023 | Hulio |
| Immunocore Limited | $23.38 | 2025 | Kimmtrak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.79 | 2022 | |
| Smith+Nephew, INC. | $15.53 | 2022 | |
| Galderma Laboratories, L.P. | $13.86 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dowlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.